Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia
DOI:
CSTR:
Author:
Affiliation:

Clc Number:

R733.7

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    OBJECTIVE: Acute promyelocytic leukemia (APL) is a specific type of hematopoietic malignancy, accounting for 10% of the de novo acute myeloid leukemia (AML). The data on long-term outcome of APL in children are limited. The aim of this study was to investigate the clinical biological features, diagnosis, prognosis and long-term survival of childhood APL. METHODS: A total of 46 children with newly diagnosed APL from April 1998 to October 2005 were enrolled into this study. Induction treatment containing all-trans retinoic acid (ATRA) plus daunorubicin (DNR) or pirarubicin (THP) was performed on these patients, followed by 6 courses of chemotherapy consolidation: DNR, homoharringtonine or etoposide plus Ara-C. A maintenance therapy was then administered once 3-6 months. The total period of treatment was 2.5 years. RESULTS: Of the 39 patients who had completed the regular treatment, 36 (92.3%) achieved a complete remission. The 5-year cumulative incidence of relapse (CIR) was 28.6%. The estimated overall survival (OS) rates at 1, 3 and 5 years were (86.1±5.8)%, (76.1±7.5)% and (70.2±8.9)%respectively, while the event free survival (EFS) rates were (78.4±6.8)%,(63.6±8.7)% and (53.1±10.0)% respectively. The 5-year OS rate of patients with WBC less than or equal to 10.0×109/L was (81.4±10.3)%, which was significantly higher than that with WBC greater than 10.0×109/L [(51.6±14.7)%, P<0.05]. Five patients with RT-PCR positive for PML/RARα S (short) subtype died eventually although all of them achieved CR, but none of the 13 patients with PML/RARα L (long) subtype died. CONCLUSIONS: Remission induction therapy with ATRA + DNR or THP is effective and safe for newly diagnosed childhood APL. The remission induction therapy combined with chemotherapy containing high/intermediate dose Ara-C can improve the long-term survival rates of APL patients. High WBC count and S subtype of PML-RARa are two poor prognostic factors for children with APL. [Chin J Contemp Pediatr, 2007, 9 (1):28-33]

    Reference
    Related
    Cited by
Get Citation

徐晓军, 石淑文, 汤永民, 宋华, 杨世隆, 魏健, 徐卫群, 潘斌华, 陈英虎, 赵芬英, 沈红强, 钱柏芹, 张玲燕, 宁铂涛.儿童急性早幼粒细胞白血病46例长期随访及预后分析[J].中国当代儿科杂志英文版,2007,9(1):28-32

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:
  • Revised:
  • Adopted:
  • Online: September 08,2009
  • Published:
Article QR Code